Data from MHRA (Medicines and Healthcare products Regulatory Agency, UK) - Curated by EPG Health - Last updated 28 February 2017

Indication(s)

Copaxone is indicated for the treatment of relapsing forms of multiple sclerosis (MS).

Copaxone is not indicated in primary or secondary progressive MS.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Load more

Related Content

More information

Category Value
Authorisation number PL 10921/0023
Orphan designation No
Date First Approved 07-04-2003
Type POM
Marketing authorisation holder Teva Pharmaceuticals Ltd.